These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 14985860

  • 1. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.
    Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J.
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF.
    mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468698
    [Abstract] [Full Text] [Related]

  • 5. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
    de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, Welters MJ, van Poelgeest MI, Melief CJ, Kenter GG, van der Burg SH.
    Cancer Immunol Immunother; 2012 Sep 19; 61(9):1485-92. PubMed ID: 22684521
    [Abstract] [Full Text] [Related]

  • 6. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
    Van Doorslaer K, Reimers LL, Studentsov YY, Einstein MH, Burk RD.
    Gynecol Oncol; 2010 Feb 19; 116(2):208-12. PubMed ID: 19555999
    [Abstract] [Full Text] [Related]

  • 7. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
    Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, Yamashita A, Nishida H, Nagasaka K, Arimoto T, Yokoyama T, Wada-Hiraike O, Oda K, Sewaki T, Osuga Y, Fujii T.
    Vaccine; 2014 Oct 29; 32(47):6233-9. PubMed ID: 25258102
    [Abstract] [Full Text] [Related]

  • 8. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
    Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH.
    Clin Cancer Res; 2004 May 01; 10(9):2954-61. PubMed ID: 15131030
    [Abstract] [Full Text] [Related]

  • 9. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
    Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML.
    Lancet; 2015 Nov 21; 386(10008):2078-2088. PubMed ID: 26386540
    [Abstract] [Full Text] [Related]

  • 10. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
    Cheng WF, Lee CN, Su YN, Chang MC, Hsiao WC, Chen CA, Hsieh CY.
    Immunology; 2005 May 21; 115(1):136-49. PubMed ID: 15819706
    [Abstract] [Full Text] [Related]

  • 11. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
    Alvarez RD, Huh WK, Bae S, Lamb LS, Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, Adams EA, Hester S, Jackson BE, Wu TC, Trimble CL.
    Gynecol Oncol; 2016 Feb 21; 140(2):245-52. PubMed ID: 26616223
    [Abstract] [Full Text] [Related]

  • 12. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ.
    J Virol; 1999 Jul 21; 73(7):5402-10. PubMed ID: 10364287
    [Abstract] [Full Text] [Related]

  • 13. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC.
    Clin Cancer Res; 2003 Nov 01; 9(14):5205-13. PubMed ID: 14614000
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM.
    J Infect Dis; 1997 Apr 01; 175(4):927-31. PubMed ID: 9086151
    [Abstract] [Full Text] [Related]

  • 15. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia.
    Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, O'Connor VM, White O, Wendt N, Martin J, Crowley JM, Edwards SJ, McKenzie AW, Mitchell SV, Maher DW, Pearse MJ, Basser RL.
    Vaccine; 2004 Nov 25; 23(2):172-81. PubMed ID: 15531034
    [Abstract] [Full Text] [Related]

  • 16. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N.
    Exp Mol Pathol; 2012 Feb 25; 92(1):185-90. PubMed ID: 22032938
    [Abstract] [Full Text] [Related]

  • 17. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
    Chan PK, Liu SJ, Cheung JL, Cheung TH, Yeo W, Chong P, Man S.
    J Med Virol; 2011 Jun 25; 83(6):1023-30. PubMed ID: 21503915
    [Abstract] [Full Text] [Related]

  • 18. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
    Yang W, Song Y, Lu YL, Sun JZ, Wang HW.
    Immunology; 2013 Aug 25; 139(4):513-22. PubMed ID: 23521696
    [Abstract] [Full Text] [Related]

  • 19. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S.
    Clin Vaccine Immunol; 2010 Sep 25; 17(9):1315-21. PubMed ID: 20668141
    [Abstract] [Full Text] [Related]

  • 20. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL.
    Cancer Res; 2003 Sep 15; 63(18):6032-41. PubMed ID: 14522932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.